tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Jade Biosciences announces first cohort dosed in Phase 1 trial of JADE101

Jade Biosciences (JBIO) has dosed the first cohort of participants in a Phase 1 healthy volunteer trial of JADE101. JADE101 is the Company’s investigational monoclonal antibody designed to selectively inhibit the activity of A PRoliferation-Inducing Ligand in patients with immunoglobulin A nephropathy (IgAN). The Company expects interim Phase 1 clinical data in the first half of 2026. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study evaluating single ascending subcutaneous doses of JADE101 in healthy adult volunteers. The trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of JADE101.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1